



**UNITAID Executive Board Meeting
26th Session
13-14 December 2016
St. Moritz-Pontresina Meeting Room
Starling Hotel
Geneva, Switzerland**

Resolution n° 1

UNITAID Strategy 2017-2021

Recalling Resolution EB24SS/2016/R4 and EB25/2016/R5, the Executive Board welcomes the presentation by the Secretariat of the UNITAID Strategy 2017-2021.

This Strategy reaffirms UNITAID's mandate in HIV/AIDS and co-infections, tuberculosis and malaria, and sets the direction for its strategic actions in the strategy period 2017-2021. It builds on the findings of the Mid-term Review of UNITAID Strategy 2013-2016, as presented to the Board during its 23rd Session, together with the analysis presented at the 24th Executive Board Special Session. It also integrates the expansion of UNITAID's scope to Reproductive, Maternal, Newborn and Child Health in the context of integrated approaches to HIV/AIDS, tuberculosis and malaria, as approved by the Board in Resolution EB25/2016/R5.

A review of UNITAID Strategy 2017-2021 will be conducted in 2019, in accordance with Resolution EB24SS/2016/R4, with a view to also considering the potential expansion of its scope.

UNITAID Executive Board approves the UNITAID Strategy 2017-2021 as in document UNITAID/EB/26/2016/3/Rev1.

A handwritten signature in blue ink, appearing to be "C. Amorim", with a long horizontal line extending to the right.

Celso Amorim
Chair of the UNITAID Executive Board